SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:his-16305"
 

Search: onr:"swepub:oai:DiVA.org:his-16305" > Utilizing microphys...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling : a case study for blood brain barrier research in a pharmaceutical setting

Fabre, Kristin M. (author)
Microphysiological Systems Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Waltham, MA, United States
Delsing, Louise (author)
Gothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningscentrum för Systembiologi,Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden / Institute of Neuroscience and Physiology, Department of Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden,Bioinformatik, Bioinformatics,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Hicks, Ryan (author)
Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
show more...
Colclough, Nicola (author)
Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
Crowther, Damian C. (author)
Neuroscience, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
Ewart, Lorna (author)
Microphysiological Systems Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
show less...
 (creator_code:org_t)
Elsevier, 2019
2019
English.
In: Advanced Drug Delivery Reviews. - : Elsevier. - 0169-409X .- 1872-8294. ; 140, s. 129-135
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics. © 2018

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Keyword

Blood brain barrier
Drug development
iPSC
Microphysiological systems
Organs-on-chips
Pharmaceutical
Stem cells
Tissue chips
Blood
Drug products
Neurodegenerative diseases
Blood-brain barrier
Induced pluripotent stem cells
On chips
Pharmaceutical company
Pharmaceutical industry
Physiological response
Physiological models
Bioinformatik
Bioinformatics
INF502 Biomarkers
INF502 Biomarkörer
Microphysiological systems
Organs-on-chips
Tissue chips
Stem cells
iPSC
Blood brain barrier
Pharmaceutical
Drug development
in-vitro model
drug discovery
efficient generation
endothelial-cells
cns
differentiation
inflammation
permeability
penetration
crispr/cas9
Pharmacology & Pharmacy

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view